Business
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22%
About this update from Actuate Therapeutics, Inc.
[{"type":"text","content":"Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in elraglusib arm compared to 4% in control armConsistent survival benefit observed across the poorest prognosis patient subgroups, including those with liver metastases and high disease burden7-40X increases in tumor-infiltrating cytotoxic immune cells and biomarker signals in the elraglusib arm reflect immunomodulatory mechanisms of action CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Nature Medicine from a randomized phase 2 clinical trial (NCT03678883) evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer. The peer-reviewed paper (DOI: 10.1038/s41591-026-04327-4), entitled “Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial” is available here. “These Phase 2 results continue to reinforce elraglusib’s potential as a combination-ready, first-line therapy with the ability to enhance the activity of standard of care chemotherapeutic backbones,” said Daniel Schmitt, Chief Executive Officer of Actuate. “The significant improvement in overall survival with an acceptable safety profile marks an important milestone for patients facing metastatic pancreatic cancer, historically one of the most difficult to treat diseases. The elraglusib containing regimen delivered a 40% improvement in median overall survival, a 38% lower risk of death, and doubled the survival rate at one year compared to the current first-line chemotherapy regimen of GnP alone. By targeting a central signaling node such as GSK-3β, elraglusib may modulate tumor cell survival, reshape tumor microenvironment, and suppress adaptive resistance pathways, enabling a broader biological impact across a broad range of cancers. Importantly, we are also a...